Drugs and patents in ATC class G03XA - Antigonadotropins and similar agents

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
DANAZOL	danazol
DANOCRINE	danazol
>Tradename	>Generic Name

Last updated: June 13, 2026

The ATC class G03XA (antigonadotropins and similar agents) spans multiple mechanisms, dosing forms, and patent families that behave differently in generic risk and enforcement. Market dynamics are driven by (1) whether products are small-molecule or peptide/biologic-like, (2) the depth of Orange Book listing and patent “evergreening” via formulation and method-of-use patents, (3) whether FDA has required pediatric exclusivity, and (4) the extent of Paragraph IV litigation affecting launch timing.

Because ATC G03XA is a class-level label that covers several distinct products, the patent landscape is best managed product-by-product, with attention to: listed FDA patents (Orange Book), composition and formulation patents, route-of-administration patents, method-of-use patents tied to indications (endometriosis, fibroids, prostate cancer, infertility protocols), and the litigation record that determines launch calendars.

Which drugs fall under ATC Class G03XA antigonadotropins and similar agents?

ATC G03XA is used in therapy indexing to group antigonadotropins and “similar agents,” but the class can include multiple active ingredients across women’s health, oncology, and reproductive medicine. In practice, the patent and exclusivity strategy hinges on whether the drug is:

Small-molecule antigonadotropins

Typically generate conventional generic pathways.
Orange Book patent listings determine whether Paragraph IV challenges can proceed before patent expiry.
Formulation and method-of-use patents can extend exclusivity indirectly.

Peptide/biologic-like GnRH-axis antagonism therapies

Tends to face higher analytical and manufacturing hurdles.
Patent estates often include device/administration systems, depot formulations, and manufacturing method claims.

Overlap with adjacent ATC groups

Some agents in G03XA overlap mechanistically with GnRH antagonists and GnRH-related therapies marketed under adjacent ATC codes. This matters for patent searches because competing products can share similar formulation and method-of-use IP even when ATC categorization differs.

What patents protect antigonadotropins and similar agents (G03XA) most often?

Featured-snippet answer: the largest “blocking” share of IP in G03XA is usually composition/active-ingredient or salt claims plus formulation (release, depot, solubility) and method-of-use (indication, dosing schedule, patient selection) claims in the Orange Book, supplemented by process and device-administration patents.

Core patent buckets that drive blocking strength

1) Composition of matter

Active ingredient, salt forms, hydrates, solvates.
Crystallographic forms or polymorphs for improved stability and bioavailability.
Any combination product patents if co-administered with other hormonal agents.

2) Formulation and delivery system patents

Sustained-release injectables and depot systems.
Particle size distributions, microsphere matrices, polymer types, and excipient systems.
Stability, reconstitution, and kit-related claims.
Device-integrated administration systems if relevant (autoinjectors, prefilled syringes).

3) Method-of-use patents

Indication-specific dosing regimens (dose, frequency, initiation/maintenance steps).
Protocols tied to reproductive cycles or stimulation schedules.
Oncology regimen schedules, including intermittent dosing.

4) Manufacturing/process patents

Scale-up methods, sterilization and aseptic processing steps.
Purification steps that impact impurity profiles.
Changes that protect “manufacturing know-how” even after composition claims are challenged.

How these categories show up in litigation

Orange Book listings drive the timing leverage for Paragraph IV.
Litigation often attacks formulation/method patents when composition is nonblocking or expired.
Settlement agreements frequently focus on narrower design-arounds (manufacturing/process tweaks and alternative release profiles) rather than full IP invalidation.

When does exclusivity end for G03XA antigonadotropin drugs, and what actually controls first generic entry?

Featured-snippet answer: generic entry is usually controlled by the latest of (1) composition/formulation patent expiry, (2) method-of-use patent expiry tied to the specific FDA-approved indication, and (3) any periods of exclusivity (including pediatric exclusivity) that delay filing or approval. The entry date is set at the intersection of FDA exclusivity and litigation outcomes.

Exclusivity mechanics that matter most

Patent expiry vs. regulatory exclusivity

Patent expiry sets the outer boundary for generic approval.
Exclusivity sets constraints on filing/approval even if some patents expire earlier.

Pediatric exclusivity

Pediatric exclusivity can extend patent-related exclusivity (commonly 6 months) if requirements are met for qualifying labeling and studies.
In G03XA, this can shift launch timing even when multiple patents expire near-simultaneously.

Evergreening via formulation and use

Sustained-release and indication-specific patents are frequent “late-expiring” items.
If a generic files an ANDA and challenges only earlier patents, later-listed patents can still block approval for the referenced indication.

Launch calendar reality

Settlement agreements are common in hormone-axis therapies where multiple patent families are still in play.
The “first filed” or “first approved” narrative often differs from the “first unblocked” outcome set by settlements.

What is the Orange Book status of antigonadotropins in G03XA?

Featured-snippet answer: the Orange Book typically contains multiple patents per NDA, spanning composition, formulation, and method-of-use. For class-level strategy, the key work is mapping each Orange Book listed patent to claim type and to which indication(s) the ANDA would carve out.

How to interpret Orange Book listings for G03XA

Look for multiple listed patents with overlapping claim families.
Identify which patents are “active” blockers for the exact submitted generic indication.
Assess whether a generic can launch via “skinny label” or carve-out to avoid later-expiring method-of-use claims.

What teams often miss

Orange Book “listed” does not equal “will be asserted,” but it defines what a generic must navigate for approval.
For G03XA, method-of-use and formulation patents can be asserted even when they appear secondary to composition claims.

Which Paragraph IV challenges are filed against antigonadotropins (G03XA), and what patterns emerge?

Featured-snippet answer: Paragraph IV campaigns in G03XA usually target (1) late-expiring formulation/depot patents and (2) indication-specific method-of-use patents, with settlement leading to delayed launches or partial carve-outs.

Common Paragraph IV patterns

ANDA filers challenge the latest-listed patents, then face injunction risk.
Some challenges are coordinated to force negotiated settlement rather than full invalidation.
If carve-outs are permitted, filers may pursue approval for non-protected indications first.

Litigation outcomes that affect commercialization

Court rulings that narrow the scope of method claims can unlock launch for that indication while leaving other indications blocked.
Settlements often include market-share and launch-date triggers that function as a de facto exclusivity extension.

What patent litigation affects G03XA antigonadotropins, including settlements and injunctions?

Featured-snippet answer: litigation and settlement are the main determinants of “practical exclusivity” in G03XA, with disputes concentrated on formulation/depot and method-of-use patents. Injunction leverage is highest where the generic cannot design around the administration or dosing regimen.

Where litigation concentrates in hormone-axis drugs

Depot/injectable performance claims: release rate, polymer matrix, particle characteristics.
Dosing regimen claims: initiation and maintenance schedules, patient population selection criteria.

Settlement agreement terms that control dates

Entered consent judgments or stipulated final judgments.
Launch dates tied to patent expiry or stipulated triggers.
Carve-out labeling and design-around commitments.

What formulations are protected for G03XA antigonadotropins (depot injectables vs oral)?

Featured-snippet answer: depot and sustained-release systems typically have the densest formulation IP. Oral or immediate-release versions usually have fewer delivery-system claims, shifting the blocking role to composition and method-of-use patents.

Depot and sustained-release injection IP themes

Polymer matrix selection and ratios.
Particle size and morphology specifications that impact in vivo release.
Sterility and manufacturing parameter claims for depot consistency.
Kit and reconstitution workflows if the product is sold as a prefilled/single-use system.

Oral formulations

Salt forms and improved stability.
Solid-state form selection and polymorph exclusivity.
Controlled-release mechanisms if present.

How does patent strength compare across common G03XA subclasses?

Featured-snippet answer: patent estates are generally stronger for sustained-release injectable antigonadotropins and for products with multiple indications, because method-of-use claims stack with formulation claims. Short-course or single-regimen products tend to have fewer method-of-use layers.

Relative strength drivers

Number of Orange Book patents per NDA.
Presence of both formulation and method-of-use claims.
Whether the product has multiple FDA-approved indications that share the same active ingredient but require different labeling.

What generic entry risks exist for G03XA antigonadotropins?

Featured-snippet answer: the highest generic entry risk lies in products with later-expiring method-of-use and depot formulation patents, especially when no carve-out is feasible for the generic label. Lower risk exists where the newest patents are invalidated or where label carving can avoid method claims.

Key entry barriers

Inability to design around formulation claims without losing bioequivalence.
Method-of-use claim infringement if labeling cannot be carved out.
Injunction risk if a court finds infringement and validity sufficient to proceed with preliminary relief.

Bioavailability and release-profile constraints

For depot/sustained-release drugs, generic substitution requires strong evidence that the release kinetics match the approved product. This can raise the cost of challenge and delay launch even if patents are navigable.

Biosimilar risk: are any G03XA agents considered biologics or biosimilar candidates?

Featured-snippet answer: if the marketed product is regulated as a biologic, biosimilar frameworks apply and patent landscapes often include manufacturing, analytical method, and formulation stability. The risk profile differs from ANDA-based generics.

What typically changes for biosimilars

Higher reliance on comparability and manufacturing controls.
Patent estates often include process patents tied to critical quality attributes.
Method-of-use claims can still block indication-by-indication approval.

How do key G03XA competitors compare on patent estate and commercialization leverage?

Featured-snippet answer: the competitive advantage typically follows the product with (1) a later-expiring formulation or method-of-use patent set, and (2) fewer viable label carve-outs for competitors.

Competitive comparison dimensions

Patent depth: number of Orange Book listings and distribution by claim type.
Litigation posture: whether disputes are settled early or sustained through trial.
Regulatory posture: whether competing products share the same indications, which increases the likelihood of infringement disputes.

Revenue exposure: which parts of G03XA are most exposed to patent expiry and entry delays?

Featured-snippet answer: exposure concentrates in top-grossing indication lines where there is limited therapeutic substitution without depot/injection continuity and where method-of-use patents block a full label entry.

Risk map framework for investment and licensing

Identify top-selling indication(s) per active ingredient.
Map each to Orange Book listed patents.
Overlay litigation outcomes and settlement launch dates.
Track whether the generic can carve out protected claims or must fully wait.

Regulatory strategy: how do FDA pathways affect patent settlement timing in G03XA?

Featured-snippet answer: ANDA vs. 505(b)(2) vs. biosimilar pathways determine the procedural posture and what patent lists are triggered for certification. Settlement calendars often align to the practical approval route rather than to theoretical earliest patent expiry.

Carve-out vs. full-label strategy

A generic that can carve out protected indications can sometimes enter earlier via narrower labeling.
A generic that targets full-label approval must navigate all relevant method-of-use patents and can face longer injunction risk.

Key takeaways

ATC G03XA’s patent landscape is heterogeneous and must be analyzed at the product level; class-level grouping masks major differences in formulation complexity and enforcement patterns.
Practical exclusivity is usually determined by Orange Book patent stacking in formulation (especially depot/sustained-release) and method-of-use, plus any pediatric or other exclusivity extensions.
Paragraph IV campaigns commonly target late-expiring formulation and method-of-use patents; settlements and carve-outs often control launch timing more than litigation invalidation.
Generic and biosimilar entry risk is highest when the product has dense depot/injectable formulation IP and multiple indication labeling that leaves no feasible carve-out.

FAQs

1) How do method-of-use patents in G03XA affect skinny-label generic approvals?
They can still block approval for the protected indication even if composition/formulation is nonblocking, unless the ANDA carve-out fully removes the infringing labeling.

2) What role do depot formulation patents play in sustained-release antigonadotropin generic challenges?
They usually drive the hardest design-around and the most frequent infringement disputes because bioequivalence depends on release kinetics and manufacturing consistency.

3) Can a generic enter one indication within a multi-indication G03XA product even if other indications remain patented?
Yes when labeling carving is permitted and certification avoids infringement of the remaining asserted method-of-use patents.

4) Do pediatric exclusivity extensions matter more than patent expiry in G03XA timing?
They can shift launch by adding regulatory exclusivity beyond patent expiry windows, changing the practical entry date.

5) What settlement terms most often determine the actual launch date for G03XA competitors?
Stipulated launch dates, carve-out labels, and design-around commitments tied to specific patents asserted in the case.

References

FDA, “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.” U.S. Food and Drug Administration.
FDA, “Biologics License Application (BLA) and Biosimilar Biological Product References.” U.S. Food and Drug Administration.
FDA, “ANDA (Abbreviated New Drug Application) Pathway.” U.S. Food and Drug Administration.
21 U.S.C. § 355 (j) (Hatch-Waxman Amendments) and patent certification framework.
42 U.S.C. § 262 (Biologics Price Competition and Innovation Act) and biosimilar pathway framework.